Citation

Spadari M, Batisse A, Guerlais M, Boucher A, Daveluy A, Le Boisselier R, Gibaja V, Eiden C, Lepelley M, Roussin A, Deheul S, Frauger E, Debruyne D. Therapie 2016; 71(6): 553-562.

Vernacular Title

Les aspects actuels de l'usage de l'ecstasy/MDMA en France.

Affiliation

Service de pharmacologie, centre d'addictovigilance de Caen, CHU Côte de Nacre, 14033 Caen cedex 09, France. Electronic address: debruyne-d@chu-caen.fr.

Copyright

(Copyright © 2016, John Libbey Eurotext)

DOI

10.1016/j.therap.2016.05.005

PMID

27371364

Abstract

Methylenedioxymethamphetamine (MDMA), the active compound of ecstasy, has been used for several years, especially by young adults to benefit of psychostimulant properties. By raising the level of neuromodulators in the synapsis, MDMA can cause psychiatric and physical injuries. After reduced supplies in 2009 (number of ecstasy seizures equal to 10 percent of those recorded in 2002), judicial authorities now observed an increased availability (a half more part of seizures in 2012 than 2010). From its "Spontaneous Notifications" data base and "deaths in connection with the abuse of medicine and substances (DRAMES)", "observation of illegal drugs and misuse of psychotropic medications" (OPPIDUM), and "observation of drug dependencies in ambulatory medicine" (OPEMA) national inquiries, the French Addictovigilance network (CEIP-A) highlighted the increasing consumption of MDMA. The way of use appeared quite unchanged: users were mainly young men between 25 and 30 years; they favored an occasional use but mainly combined other products such as alcohol, cannabis and other stimulants. Severity of the clinical cases, based on hospital care and forensic data, could be consistent with the higher amounts of MDMA measured in pills.

Copyright © 2016 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.

Language: fr